ERBB2 and Hypertension: Based on these conflicting results, studies have focused on risk factors that may influence trastuzumab-mediated cardiotoxicity in the presence of the HER2 lle655Val SNP including alcohol consumption, BMI, diabetes, hypertension, and combination treatment with anthracyclines [229].